Trial Profile

A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With TAK-438 Versus Quadruple Therapy With Lansoprazole

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amoxicillin (Primary) ; Clarithromycin (Primary) ; Tripotassium dicitratobismuthate (Primary) ; Vonoprazan (Primary) ; Lansoprazole
Indications Helicobacter pylori infections
Focus Adverse reactions; Pharmacokinetics
Sponsors Takeda

03 Jun 2021 Results published in the British Journal of Clinical Pharmacology
19 Jul 2017 Status changed from recruiting to completed.
18 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Apr 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com